Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
Source: View publication →
In patients with symptomatic heart failure and reduced ejection fraction, the addition of the ACE inhibitor enalapril to conventional therapy significantly reduced all-cause mortality and hospitalizations for worsening heart failure.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SOLVD treatment trial was a watershed moment in cardiology that firmly established angiotensin-converting-enzyme (ACE) inhibitors as a foundational, life-saving therapy for heart failure with reduced ejection fraction (HFrEF). By demonstrating a definitive mortality benefit, it shifted the paradigm of heart failure management from solely providing hemodynamic and symptomatic relief (with digitalis and diuretics) to modifying disease progression via neurohormonal blockade.
Historical Context
Prior to SOLVD, the 1987 CONSENSUS trial demonstrated a massive mortality benefit for enalapril, but it was restricted to a small population with severe, NYHA Class IV heart failure. SOLVD expanded this evidence base to a much larger cohort of patients with mild-to-moderate symptomatic heart failure (90% NYHA Class II-III), profoundly altering clinical guidelines to mandate ACE inhibitors as first-line therapy for symptomatic HFrEF. A companion trial, SOLVD-Prevention (published in 1992), subsequently evaluated the drug in asymptomatic left ventricular dysfunction.
Guided Discussion
High-yield insights from every perspective
By what mechanism does enalapril, an ACE inhibitor, reduce mortality in patients with heart failure with reduced ejection fraction, and why did the SOLVD trial represent a paradigm shift from historical therapies like digoxin or loop diuretics?
Key Response
Enalapril blocks the conversion of angiotensin I to angiotensin II, decreasing sympathetic activity, vasoconstriction, and aldosterone secretion. Unlike diuretics and digoxin, which mainly provide symptomatic relief by altering volume status and contractility respectively, ACE inhibitors modify the underlying neurohormonal axis, preventing maladaptive cardiac remodeling and actually improving survival.
A patient with symptomatic HFrEF is started on enalapril based on the SOLVD trial protocol. What key laboratory parameters and vital signs must be monitored within the first 1-2 weeks of initiation, and how would you manage a mild, asymptomatic 20 percent increase in serum creatinine?
Key Response
Clinicians must monitor blood pressure for hypotension, serum potassium for hyperkalemia due to decreased aldosterone, and serum creatinine due to efferent arteriole vasodilation reducing GFR. A mild increase in creatinine up to 30 percent is expected and acceptable; the ACE inhibitor should be continued unless hyperkalemia or severe, progressive renal failure occurs.
The SOLVD treatment trial established ACEi in symptomatic HFrEF, while the parallel SOLVD prevention trial looked at asymptomatic LV dysfunction. How does the concept of neurohormonal blockade differ in its clinical impact between the presymptomatic versus symptomatic stages of heart failure regarding ventricular remodeling and survival?
Key Response
While both symptomatic and asymptomatic patients benefit from ACE inhibitors, symptomatic patients in the treatment arm saw a significant reduction in overall mortality, whereas the asymptomatic prevention arm primarily saw a delay in the onset of symptomatic HF and reduced HF hospitalizations. This highlights that early neurohormonal blockade mitigates progressive adverse LV remodeling before clinical volume overload manifests, though the absolute mortality benefit is most pronounced once symptoms develop.
Reflecting on the evolution of HFrEF therapy since the SOLVD trial, how do we contextualize the historical use of ACE inhibitors against contemporary foundational therapies like ARNIs when teaching trainees about the sequence and speed of initiating guideline-directed medical therapy?
Key Response
SOLVD established the stepwise historical approach to HF therapy, starting with an ACEi. However, modern teaching must emphasize that ARNIs have largely supplanted ACE inhibitors as first-line therapy per PARADIGM-HF, and contemporary practice favors rapid, simultaneous initiation of low-dose quadruple therapy (ARNI, beta-blocker, MRA, SGLT2i) rather than the historical slow, sequential titration championed in the SOLVD era.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In the SOLVD trial, patients were randomized to enalapril or placebo on top of conventional therapy, which evolved over time. How does the dynamic nature of background therapy in long-term cardiovascular outcome trials complicate the statistical estimation of the specific treatment effect, and what modern trial designs address this?
Key Response
When background therapy is left to the discretion of the treating physician and evolves over the trial period, it introduces time-varying confounding and can dilute the treatment effect if the control group receives newer, effective off-protocol therapies (drop-in). Modern trials use active comparators, pragmatic platform designs, or stringent run-in periods with standardized background GDMT to isolate the incremental efficacy of the novel agent.
The SOLVD trial utilized a pre-randomization run-in period to ensure patient tolerability to enalapril. How does this active run-in design impact the external validity and the intention-to-treat analysis, and how should editors weigh this when evaluating the safety profiles of drugs in modern clinical trial submissions?
Key Response
An active run-in period excludes patients who experience early adverse effects like severe hypotension or renal dysfunction, artificially lowering the adverse event rate in the randomized phase and potentially exaggerating the drug's safety and tolerability in a real-world, unselected population. Reviewers must flag this as a threat to external validity and demand clear reporting of pre-randomization exclusion rates and baseline characteristics of run-in failures.
Given that the SOLVD trial firmly embedded ACE inhibitors into Class I recommendations for HFrEF, how should current ACC/AHA guidelines grade the recommendation for ACE inhibitors now that ARNIs have demonstrated superiority, and under what specific clinical scenarios does enalapril remain a Class 1 preferred agent?
Key Response
Current ACC/AHA guidelines prioritize ARNIs with a Class 1 recommendation over ACEi for HFrEF based on superior morbidity and mortality outcomes. However, ACE inhibitors like enalapril maintain a Class 1 recommendation when ARNI administration is not feasible, such as due to cost, insurance access, or specific intolerances, ensuring that the legacy survival benefit proven in SOLVD remains accessible to all patients.
Clinical Landscape
Noteworthy Related Trials
CONSENSUS Trial
Tested
Enalapril
Population
Patients with severe (NYHA IV) congestive heart failure
Comparator
Placebo
Endpoint
All-cause mortality
SAVE Trial
Tested
Captopril
Population
Patients with asymptomatic left ventricular dysfunction post-myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
PARADIGM-HF Trial
Tested
Sacubitril/Valsartan
Population
Patients with symptomatic heart failure with reduced ejection fraction
Comparator
Enalapril
Endpoint
Composite of cardiovascular death or heart failure hospitalization
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis